OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Tasadenoturev active in DIPG	1248
From little subclones grow mighty oaks	1205
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	853
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	838
Sacituzumab govitecan plus pembrolizumab improves outcomes	775
Hodgkin lymphoma: great progress with room for improvement	686
Ecological management of the microbiota in patients with cancer	680
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	581
A new standard of care for advanced-stage urothelial carcinoma	556
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	518
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	517
Novel ICI–TKI combination improves HCC outcomes	497
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles	482
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown	476
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	475
Current understanding and management of CAR T cell-associated toxicities	462
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	398
Gut microbiota in colorectal cancer development and therapy	361
Ponatinib superior to imatinib in Ph+ ALL	344
Mortality is similar with active monitoring	343
From ESMO 2022	330
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	327
Sacituzumab tirumotecan improves OS in mTNBC	321
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	321
Belzutifan as a new option in pheochromocytomas and paragangliomas	318

Emerging trends in the global burden of colorectal cancer	315
Understanding and overcoming multidrug resistance in cancer	313
Humanized mouse models for immuno-oncology research	311
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	309
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	303
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	299
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	279
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	271
Craniospinal irradiation improves leptomeningeal metastasis control	257
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	254
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	251
Vebreltinib effective in MET-amplified NSCLC	242
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	235
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	220
Improving outcomes in patients with oesophageal cancer	213
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	207
MicroRNAs in oncology: a translational perspective in the era of AI	204
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	197
Biomarkers for immunotherapy of hepatocellular carcinoma	195
Spatial landscapes of cancers: insights and opportunities	195
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	187
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	183
SHINE a light: frontline ibrutinib for MCL	168
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	163
Women with clinically node negative breast cancer can safely avoid axillary surgery	162
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	159
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	158
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	144
Prospective comparisons support the use of navigational bronchoscopy	140
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	132
Synergistic integration of regional and systemic therapies in uveal melanoma	131
From ESMO 2023: advances in lung cancer	131
DREAMseq of therapy for BRAF-mutant melanoma	131
Targeting chromosomal instability in patients with cancer	130
Mitigating acute chemotherapy-associated adverse events in patients with cancer	128
Circulating tumour DNA — looking beyond the blood	127
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	120
Long-term outcomes following CAR T cell therapy: what we know so far	120
Multiomics STEP up in correlative analysis of response to CAR T cells	116
From the ESMO Congress 2023	113
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	111
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	111
Sentinel lymph node biopsy improves surgical management of cervical cancer	110
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	105
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	103
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	102
Author Correction: Innovative approaches for lung cancer screening and interception	101
Claudin 18.2 as a novel therapeutic target	100
Lung cancer in patients who have never smoked — an emerging disease	97
Enhancing immunotherapy with tumour-responsive nanomaterials	95

Newly approved cancer drugs in China — innovation and clinical benefit	95
Clinical implications of T cell exhaustion for cancer immunotherapy	95
Targeted biopsy reduces detection of clinically insignificant cancer	94
T-DXd effective as second-line therapy in G/GEJ cancers	93
Second-line tarlatamab improves OS in SCLC	92
Less-frequent surveillance is noninferior to annual mammography	90
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	88
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	85
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology	83
Translating biological insights into improved management of endometrial cancer	82
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics	81
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC	81
Barriers in access to oncology drugs — a global crisis	80
Two decades of advances in clinical oncology — lessons learned and future directions	80
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	80
BrECADD raises the bar in classical Hodgkin lymphoma	74
HSCT prolongs remission of high-risk CTCLs	69
Promising OS with oncolytic virotherapy	66
Thermal ablation is safer than resection of colorectal liver lesions	66
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	63
GPRC5D-CAR T cells active in MM	61
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	59
Promise with co-administration of CAR T cells	59
Engineering platelets as cancer therapeutics	57
Efficacy of TILs confirmed	56
Multidisciplinary management of meningiomas in the era of precision oncology	56
Non-financial conflicts of interest	56
Cured but breathless: the growing burden of DIILD in cancer survivors	55
Nirogacestat effective in desmoid tumours	55
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	54
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	53
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	53
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	50
The current state of the art and future trends in RAS-targeted cancer therapies	47
Repotrectinib effective in ROS1-fusion-positive NSCLC	46
Exploiting bacteria for cancer immunotherapy	46
KN046 shows tolerability and activity in TNBC	44
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	43
Neoadjuvant pembrolizumab improves outcomes	40
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	38
Problematic crossovers in cancer drug trials	38
The emerging roles of γδ T cells in cancer immunotherapy	31
Clinical implementation of multi-cancer early detection tests: can we find a path forward?	31
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	30
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	30
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	30
CAR T cells induce durable remission of neuroblastoma	29
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	29
GPRC5D as a novel immunotherapeutic target in multiple myeloma	29
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons	29
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours	29
The changing landscape of oncology clinical trials in Latin America	29
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	28
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	28